ADMA Adma Biologics Inc

Price (delayed)

$1.29

Market cap

$171.27M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.7

Enterprise value

$223.13M

ADMA Biologics is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics for the treatment of immunodeficient patients at risk for infection and others at ...

Highlights
ADMA's revenue has surged by 56% year-on-year and by 21% since the previous quarter
ADMA's gross margin has soared by 52% YoY and by 45% QoQ
ADMA's quick ratio is down by 43% YoY
The company's net income fell by 20% YoY

Key stats

What are the main financial stats of ADMA
Market
Shares outstanding
132.77M
Market cap
$171.27M
Enterprise value
$223.13M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
1.48
Price to sales (P/S)
2.83
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
3.84
Earnings
Revenue
$58.11M
EBIT
-$60.97M
EBITDA
-$56.14M
Free cash flow
-$135.09M
Per share
EPS
-$0.7
Free cash flow per share
-$1.06
Book value per share
$0.87
Revenue per share
$0.46
TBVPS
$1.78
Balance sheet
Total assets
$232.81M
Total liabilities
$121.22M
Debt
$94.26M
Equity
$111.59M
Working capital
$153.17M
Liquidity
Debt to equity
0.84
Current ratio
9.42
Quick ratio
3.63
Net debt/EBITDA
-0.92
Margins
EBITDA margin
-96.6%
Gross margin
-16.3%
Net margin
-126.7%
Operating margin
-106.3%
Efficiency
Return on assets
-34%
Return on equity
-76.7%
Return on invested capital
-26.4%
Return on capital employed
-28.4%
Return on sales
-104.9%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

ADMA stock price

How has the Adma Biologics stock price performed over time
Intraday
7.5%
1 week
8.4%
1 month
-3.01%
1 year
-46.47%
YTD
-33.85%
QTD
-19.38%

Financial performance

How have Adma Biologics's revenue and profit performed over time
Revenue
$58.11M
Gross profit
-$9.46M
Operating income
-$61.77M
Net income
-$73.61M
Gross margin
-16.3%
Net margin
-126.7%
ADMA's revenue has surged by 56% year-on-year and by 21% since the previous quarter
ADMA's gross margin has soared by 52% YoY and by 45% QoQ
The gross profit has grown by 33% from the previous quarter and by 25% YoY
The company's net margin rose by 23% YoY and by 19% QoQ

Growth

What is Adma Biologics's growth rate over time

Valuation

What is Adma Biologics stock price valuation
P/E
N/A
P/B
1.48
P/S
2.83
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
3.84
The EPS has grown by 18% year-on-year and by 10% since the previous quarter
The price to book (P/B) is 72% lower than the 5-year quarterly average of 5.2 and 33% lower than the last 4 quarters average of 2.2
The equity has increased by 45% year-on-year
ADMA's price to sales (P/S) is 60% lower than its 5-year quarterly average of 7.0 and 33% lower than its last 4 quarters average of 4.2
ADMA's revenue has surged by 56% year-on-year and by 21% since the previous quarter

Efficiency

How efficient is Adma Biologics business performance
ADMA's ROE is up by 26% YoY and by 11% QoQ
The return on sales has grown by 22% year-on-year and by 19% since the previous quarter
The company's return on invested capital rose by 9% QoQ and by 9% YoY
The company's return on assets rose by 8% YoY and by 6% QoQ

Dividends

What is ADMA's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for ADMA.

Financial health

How did Adma Biologics financials performed over time
Adma Biologics's total assets is 92% more than its total liabilities
ADMA's quick ratio is down by 43% YoY
Adma Biologics's total assets has increased by 22% YoY
The company's debt is 16% lower than its equity
The equity has increased by 45% year-on-year
Adma Biologics's debt to equity has decreased by 33% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.